NCT04168892View on ClinicalTrials.gov

Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response

CompletedOBSERVATIONAL
Enrollment

160

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Ovarian Response
Interventions
DRUG

150 IU of HMG in patients with age ≤ 35 years

The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.

DRUG

225 IU of HMG in patients with age > 35 years

The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.

Trial Locations (1)

90144

ANDROS Day Surgery Clinic, Reproductive Medicine Unit, Palermo

All Listed Sponsors
lead

Andros Day Surgery Clinic

OTHER

NCT04168892 - Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response | Biotech Hunter | Biotech Hunter